Additionally, anti–PD-1 and anti–CTLA-4 ICIs are known to have distinct mechanisms of action, with anti–CTLA-4 agents more capable of activating and expanding T cells, particularly CD4+ T cells, in the tumor draining lymph nodes, leading to increased trafficking of activated T cells into the TME (27–30). This evidence concerns the gene CTLA4 and neoplasm.